Scholar Rock reports 61,020 inducement shares in Scholar Rock stock update

Published on 10/20/2026 at 13:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seven hires received 61,020 shares on October 16, 2026. Scholar Rock stock costs EUR 35.85 at Lang & Schwarz on October 20, 2026 at 1:33 p.m. CEST.

Regulatory progress and financial base

Scholar Rock granted 61,020 inducement shares to seven new hires on October 16, 2026.
Second-quarter 2026 net loss reached USD 109.9 million, while cash and securities totaled USD 492 million.
Scholar Rock stock trades at EUR 35.85 at 1:33 p.m. CEST at Lang & Schwarz on October 20, 2026.

SRRK, US80706P1030, Illustration mit AI erstellt.

Scholar Rock Holding Corporation (US80706P1030) granted inducement equity awards covering 61,020 shares to seven new employees on October 16, 2026, while its stock traded at EUR 35.85 at Lang & Schwarz on October 20, 2026 at 1:33 p.m. CEST. The awards add a personnel and commercialization detail to the biotechnology company's post-approval execution.

61,020 shares mark hiring push

According to StockTitan on October 16, 2026, the awards comprised options covering 17,461 shares and restricted stock units covering 43,559 shares. The options carry an exercise price of USD 41.94, equal to the closing price of the common stock on October 12, 2026.

What does the cash position show?

Scholar Rock's second-quarter 2026 results showed a GAAP net loss of USD 109.9 million and an operating loss of USD 108.9 million. Benzinga reported that cash, cash equivalents and marketable securities totaled USD 492 million at the end of the quarter, including USD 63 million in net proceeds from the company's at-the-market program.

Three dated steps in 2026

On September 11, 2026, the U.S. Food and Drug Administration approved ISEMBYLD, or apitegromab, for eligible patients with spinal muscular atrophy, as Scholar Rock stated on October 8, 2026. On October 8, 2026, the company resubmitted its European marketing authorization application with an alternate fill-finish facility. On October 16, 2026, it disclosed the 61,020-share inducement package for seven hires, according to StockTitan.

The next regulatory date

The company anticipates an opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in the first half of 2027, according to Scholar Rock.

Stock price and execution

The current market picture combines a EUR 35.85 Lang & Schwarz quote with a recent regulatory filing, a new-hire equity package and a second-quarter cash balance of USD 492 million. For investors, the key issue is whether the company can convert regulatory progress and its cash position into a durable commercial launch.

The further course of trading is shown by the continuously updated real-time quote of Scholar Rock stock.